Peter Pitts Letter to the Editor in the LA Times

Peter Pitts Letter to the Editor in the LA Times

LA Times
By Peter Pitts
April 15,2007

Price controls on Medicare drugs

Re "Aid for Medicare patients sought," April 11

Although the article states that "Democrats say the government could save money if it used its massive purchasing power to negotiate with pharmaceutical companies," there is little evidence to support their claim.

First, it's not clear that allowing the government to negotiate prices would yield any savings. According to a recent report from the nonpartisan Congressional Budget Office, "Government price negotiation would not yield lower drug prices compared to current law."

Second, Democrats cite the Department of Veterans Affairs' drug benefit as a good model for Medicare Part D. But under the VA model, drug companies must sell their products to the government at a price that is at least 24% less than the non-federal average manufacturer's price. In other words, the VA institutes price controls.

Medicare covers well over 40 million seniors. If price controls are extended to such a large segment of the market, they inevitably would result in reduced consumer choices and stifled drug innovation.

PETER PITTS

Director, Center for Medicine in the Public Interest,
New York

Featured

Animal health and human health are inextricably linked
  May 15, 2012  
Drug Shortages and the Role of the Middle Man
 April 13, 2012  
Obamacare's Medical Mercenaries
 April 13, 2012  

Social Networks

Receive latest news & event updates
Provide email below:

Like CMPI on Facebook
Follow CMPI on Twitter
Connect with CMPI on LinkedIn
Watch our Videos on CMPI YouTube Channel
Subscribe to Receive CMPI RSS Feeds